Skip to main content

IBB

ETF

IBB

ETF
Health Care
Biotechnology

Performance overview

IBB Price
Price Chart

Forward-looking statistics

Beta
0.67
Risk
17.93%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Fund Profile

An ETF that tracks the performance of the biotechnology sector in the United States.

Fund info

An ETF that tracks the performance of the biotechnology sector in the United States.

Investing methodPassively Managed
DiversifiedNo
Expense ratio0.45%
Asset classEquities

Company info

SectorHealth Care
IndustryBiotechnology
Website
AUM$10.0B

Security info

ExchangeNASDAQ
Type of shareN/A
Earnings per share (EPS)
Dividend per share$0.48
Revenue per share
Avg trading volume (30 day)$243M
Avg trading volume (10 day)$190M
Put-call ratioN/A

Macro factor sensitivity

Growth+0.7
Credit+3.1
Liquidity+0.2
Inflation-2.2
Commodities-0.2
Interest Rates-1.2

Upcoming events

Next earnings day
Next dividend day
Ex. dividend dayMarch 18, 2025

News

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

The iShares Biotechnology ETF (IBB) made its debut on 02/05/2001, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.

Zacks Investment Research (June 18, 2025)
Fast Money: WTI, IBB, UBER, CAT

The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.

CNBC Television (June 13, 2025)
Trump Says Pharmaceutical Tariffs Coming in Near Future

President Donald Trump said tariffs on pharmaceuticals will be coming in the 'not too distant future' and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporters Monday in the Oval Office.

Bloomberg Markets and Finance (April 14, 2025)
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages

President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told CNBC.  The tariffs could disrupt the complex pharmaceutical supply chain, potentially driving up the prices of drugs in the U.S. and exacerbating shortages of critical medicine.

CNBC (April 11, 2025)
Biotech walks a 'tightrope' amid unclear funding, regulations

Earlier this week, the Trump administration froze and then rescinded the freeze on federal funding for several programs, including research funding that the biotech industry relies on. Clear Street senior equity analyst and director of research, Mara Goldstein, sits down with Julie Hyman and Josh Lipton on Market Domination to discuss how to play the biotech sector as Trump's second term in the White House is underway.

Yahoo Finance (January 31, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free